腹腔镜下结直肠癌根治术中联合腹腔热灌注化疗的临床研究

目的:探讨腹腔镜下结直肠癌根治术中联合腹腔热灌注化疗(IHPC)的安全性及可行性。方法:将120例进展期结直肠癌患者随机分成治疗组和对照组,每组各60例。两组患者均接受腹腔镜下结直肠癌根治术,治疗组术中行IHPC联合术后m FOLFOX6方案静脉化疗;对照组单纯行术后m FOLFOX6方案静脉化疗。比较两组患者手术相关指标、术后恢复情况、术后并发症、不良反应、局部复发率及远处转移率。结果:两组患者在手术相关指标、术后恢复情况、术后并发症方面差异均无统计学意义(均P>0.05);治疗组术后低蛋白血症和低钠血症的发生率明显高于对照组(20.0%vs.6.7%;15.0%vs.3.3%,均P<0.05);腹腔局部复发率和远处转移率明显低于对照组(6.7%vs.18.3%;8.3%vs.23.3%,均P<0.05);两组短期总生存率相当(P>0.05)。结论:腹腔镜下结直肠癌根治术中IHPC联合术后静脉化疗安全可靠,对局部复发及远处转移疗效较好。     

进展期结直肠癌根治术后腹腔热灌注化疗联合全身化疗的临床相关性研究

目的评估进展期结直肠癌患者在行腹腔镜下根治性切除术后采取腹腔热灌注化疗联合全身化疗的临床疗效及安全性。方法选择两组在我院收治的78例进展期结直肠癌患者,一组为联合化疗组(39例),在行腹腔镜下结直肠癌根治性切除术后,首先行腹腔热灌注化疗(IHIPC)3次,然后再采用全身化疗,方案为(XELOX);另一组为单一化疗组(39例),在行腹腔镜下结直肠癌根治性切除术后,单纯采用全身化疗,方案为(XELOX)。对两组患者的临床疗效及安全性进行对比分析。结果联合化疗组患者在化疗后,其KPS评分升高率为53.85%,单一化疗组在化疗后,其KPS评分升高率为25.64%,两者差异存在统计学意义(P0.05);两组患者的各种不良反应发生率无明显差异(P0.05);对两组患者术后随访5年,联合化疗组的患者在第1、3、5年的生存率分别为94.87%、84.62%、69.23%,单一化疗组分别为92.31%、64.10%、46.15%,两组患者在第3、5年的生存率进行比较,其差异存在统计学意义(P0.05)。结论进展期结直肠癌患者在行腹腔镜下根治性切除术后采取腹腔热灌注化疗联合全身化疗,可能提高了患者的术后生存质量及生存率,且不良反应也无明显增加。     

T4期结直肠癌根治术后早期腹腔热灌注化疗的临床研究

目的:探讨T4期结直肠癌患者根治术后早期行腹腔热灌注化疗(HIPEC)的可行性、安全性及短期临床疗效。方法:回顾性分析2011年1月—2013年6月收治的96例T4期结直肠癌患者资料,其中48例于术后第5~6天开始行HIPEC(1次/d,共3次),术后1个月内行第1次m FOLFOX6方案全身静脉化疗,共6疗程(HIPEC组);另48例仅行相同方案的全身静脉化疗(对照组)。比较两组患者的不良反应、并发症、术后1、2年复发率、生存率及生存质量情况。结果:HIPEC及全身静脉化疗均顺利完成;两组均无手术相关死亡,均未出现切口感染、吻合口瘘、粘连性肠梗阻等并发症。两组患者骨髓抑制、恶心呕吐、肝功能损害差异均无统计学意义(均P0.05);HIPEC组术后1、2年复发率均低于对照组(2.1%vs.20.8%;6.3%vs.31.3%,均P0.05);两组术后1年生存率差异无统计学意义(P0.05);HIPEC组术后2年生存率高于对照组(81.3%vs.58.3%,P0.05);HIPEC组生存质量评分升高比例明显高于对照组(75.0%vs.25.0%,P0.05)。HIPEC组中,结肠癌患者的中位生存时间长于直肠癌患者(32个月vs.18个月,P0.05)。结论:T4期结直肠癌患者根治术后早期行HIPEC可有效控制腹腔复发、转移,提高患者近期生存率及生存质量,无明显毒副作用,安全可行。     

腹腔镜结直肠癌根治术的临床研究

目的：探讨腹腔镜行结直肠癌根治术的可行性。方法：回顾性分析2001年来41例腹腔镜结直肠癌手术病人临床和病理资料。结果：41病例中无围手术期死亡。腹腔镜手术时间平均为128min，出血量5～100m1，淋巴结清除数平均12．9个(3～33个)。随访1个月至2年，患者均健在，目前尚未发现有小切13和穿刺孔转移。结论：腹腔镜技术在结直肠恶性肿瘤根治性手术中有广阔的应用前景。     

腹腔热灌注化疗治疗晚期结直肠癌的疗效分析

目的探究腹腔热灌注化疗(HIPEC)治疗晚期结直肠癌(CRC)并腹膜转移病人的临床疗效及预后。方法 2016年4月～2017年4月期间内我院收治的CRC伴腹膜转移病人71例。根据术后化疗方法不同将其分为观察组(34例)和对照组(37例);其中,观察组术后采用HIPEC,对照组采用常规静脉化疗方案进行治疗。治疗满6个周期后,比较两组病人的临床疗效,血清肿瘤志物、生存质量、生存率及不良反应等情况。结果观察组病人治疗总有效率和疾病控制率分别为67.6%和87.3%,对照组分别为40.5%和62.2%,两组比较差异有统计学意义(P0.05);治疗后观察组血清糖链抗原19-9(CA19-9)、CA125及癌胚抗原(CEA)分别为(24.21±1.98)、(37.97±2.93)和(16.26±2.02),对照组分别为(30.9±3.05)、(44.53±3.34)和(19.68±1.94),两组比较差异有统计学意义(P0.05)。观察组治疗后KPS评分优于对照组,差异有统计学意义(P0.05);经治疗后两组相关并发症发生率无明显差异(P0.05)。结论 HIPEC方案可提高CRC病人化疗的临床疗效,有效控制肿瘤进展并改善病人的免疫功能及生存质量。     

腹腔热灌注化疗对结直肠癌患者细胞免疫功能的影响

观察腹腔热灌注化疗对结直肠癌患者术后细胞免疫功能的影响。选择2013年1月—2015年12月我院结直肠癌患者50例,随机分为实验组和对照组,每组各25例。对照组患者常规行开腹结直肠癌根治术,实验组在常规开腹根治术基础上行腹腔热灌注化疗。两组病例均在手术前1天、手术后第3、5、7天分别抽取静脉血,以流式细胞仪测定T淋巴细胞亚群CD3~+、CD4~+、CD8~+和NK细胞数量,并计算CD4~+/CD8~+比值。术后第3天两组患者外周血CD3~+、CD4~+、CD4~+/CD8~+及NK细胞活性较术前均明显下降(P0.05),实验组与对照组比较无明显差异(P0.05)。实验组术后第5天上述指标迅速恢复,至第7天接近术前水平,而对照组术后7 d内仍持续处于低水平。两组比较差异有统计学意义(P0.05)。腹腔热灌注化疗可以提高结直肠癌患者术后细胞免疫功能。     

腹腔镜结直肠癌根治术

自1990年Jacobs和Fowler先后在腹腔镜下行右半结肠切除术和乙状结肠切除术获得成功以来,腹腔镜结直肠癌手术的可行性和优点已经得到了广泛认可.我院2003年9月至2008年9月施行腹腔镜结直肠癌根治术共32例,取得了满意疗效.     

腹腔热灌注化疗治疗晚期结直肠癌50例疗效观察

为观察腹腔热灌注化疗治疗晚期结直肠癌患者的疗效,将晚期结直肠癌患者100例随机分为A组和B组,每组50例.A组患者采用腹腔热灌注化疗治疗,B组患者采用腹部局部射频治疗,比较2组患者的疗效和不良反应发生情况.结果显示,A组患者总有效率为98.00％,明显高于B组的72.00％(P<0.05);A组患者骨髓抑制、肝功能损伤...     

腹腔镜辅助腹腔热灌注化疗治疗结直肠癌引起的恶性腹水临床疗效及安全性

目的探讨腹腔镜辅助腹腔热灌注化疗(HIPEC)治疗结直肠癌引起恶性腹水的临床疗效及安全性。 方法回顾性分析2014年1月至2015年5月诊断结直肠癌并合并恶性腹水患者35例,分为原发组19例和术后复发组16例,均进行腹腔镜辅助置管腹腔热灌注化疗。采用SPSS 20.0统计分析软件进行分析,HIPEC治疗有效率和术后并发症采用卡方检验;KPS评分采用均数±标准差表示,独立t检验,P<0.05为差异有统计学意义。 结果HIPEC治疗后总有效率为100%,其中完全缓解率85.7%(30/35);两组患者灌注后4周KPS评分较灌注前上升0～20分,原发组上升更明显(P＝0.000);术后复发组不良反应发生率显著高于原发组(P<0.05)。 结论腹腔镜辅助置管HIPEC能缓解结直肠癌引起的恶性腹水,提高患者的生活质量,具有良好的安全性。     

根治术后行肠造口的结直肠癌病人行腹腔热灌注化疗的可行性和安全性分析

目的 探讨根治术后行肠造口的结直肠癌病人行腹腔热灌注化疗的可行性和安全性。方法 2021年4月～2021年12月我院收治的结直肠癌病人184例，按治疗方法将其分为根治术+腹腔热灌注化疗(117例)、根治术+肠造口(36例)、根治术+肠造口+腹腔热灌注化疗(31例)三组。通过腹腔热灌注化疗曲线分析对管道通畅性进行评价，按美国卫生及公共卫生部公布的常见不良事件评价标准(CTCAE 5.0)对治疗观察期间发生的不良事件进行分级。采用Logistic回归分析影响腹腔热灌注化疗管道通畅性的独立危险因素，采用χ²检验和Fisher精确检验分析腹腔热灌注化疗对根治术后行肠造口的结直肠癌病人围手术期不良事件发生的影响。结果148例根治术后行腹腔热灌注化疗的病人共计完成255例次腹腔热灌注化疗，其中125例次(49.0%)灌注过程通畅，84例次(32.9%)调整后通畅，46例次(18.0%)灌注过程不通畅。Logistic回归分析结果表明，肠造口是根治术后行腹腔热灌注化疗的结直肠癌病人发生非完全通畅事件和完全堵塞事件的独立危险因素(P均<0.05)。67例根治术后行肠造口的结...     

结直肠癌术前区域动脉灌注化疗的临床研究

近年来区域化疗对实体肿瘤治疗作用日益受到重视,但对结直肠癌术前区域动脉灌注化疗报告极少。作者对30例结直肠癌患者行术前选择性区域动脉灌注化疗,术后标本组织病理学观察发现,在肿瘤边缘出现明显坏死灶,区别于发生在肿瘤中心的自然坏死。所有病例均发现癌细胞发生核固缩、碎裂、胞浆凝固、坏死,细胞间质水肿、纤维增生、炎性细胞浸润,血管出现内膜增生、血管炎及血栓形成,均以轻到中度变化     

腹腔镜结直肠癌根治术学习曲线

目的探讨外科医师如何尽快掌握腹腔镜结直肠癌根治术。方法分析2000年9月至2003年5月由同一组医师完成的50例腹腔镜结直肠癌根治术,按手术先后次序分5组,每组10例,比较各组手术时间、术中出血量、术后肛门排气时间、术后住院天数和各组病灶的位置和术后并发症发生率、腹腔镜手术占同期同类手术比例和3站淋巴结清扫数目及其总数的差异。结果A组手术时间由(314.5±34.4)min至E组降为(186.0±27.6)min(P=0.000),术中出血量由(94.0±25.5)ml降至(15.5±18.3)ml(P=0.000)。肛门排气时间、住院天数、病灶的位置、术后并发症发生率、3站淋巴结清扫数及总数各组比较,差异均无显著性意义(P>0.05)。但E组无术中并发症及中转开腹。腹腔镜手术占同期同类手术总数由A组的15.2%(10/66)至E组上升为47.6%(10/21)(P=0.004);全组吻合口瘘发生率为2.0%(1/50),局部复发率为4.0%(2/50)。结论腹腔镜结直肠癌根治术学习曲线大约为40例,即可达到较熟练程度。     

术后早期腹腔热灌注化疗对结直肠癌近期生存率的影响

探讨术后早期腹腔热灌注化疗对直肠癌患者近期生存率的影响。回顾性分析2013年9月—2014年9月在我院接受治疗的直肠癌患者的临床资料,根据化疗方式分为单纯静脉化疗组(100例)、静脉化疗+腹腔热灌注化疗组(121例)。观察两组患者1年内的复发率、转移率、生存率及生活质量的差别。比较不同临床病理特征直肠癌患者1年生存率的差异,分析影响结直肠癌患者近期生存率的因素。静脉化疗+腹腔热灌注化疗组复发、转移率明显低于单纯静脉化疗组,而1年生存率明显高于单纯静脉化疗组,差异具有统计学意义(P0.05)。治疗前两组患者躯体功能、躯体角色和肢体疼痛等生活质量评分无明显差异;治疗后两组患者上述指标均较治疗前升高,且腹腔热灌注化疗组增高更明显(P0.05)。分化程度、T分期、淋巴结转移和化疗方式是影响患者1年生存率的因素(P0.05)。术后早期腹腔热灌注化疗对结直肠癌有较好的治疗效果,可明显提高近期生存率,提高其生活质量。     

浆膜受侵的结直肠癌术后腹腔化疗联合静脉化疗的临床研究

Objective To compare the clinical efficacy of postoperative intraperitoneal chemotherapy combined with systemic chemotherapy to systemic chemotherapy alone for serosa-involved colorectal cancer. Methods According to the criteria of serosa-involving in colorectal cancer, 332 cases were divided into 2 groups prospectively without randomization. Study group (n=166) was treated with intraperitoneal chemotherapy combined with systemic chemotherapy, and control group (n=166) with systemic chemotherapy alone. Incidence of local recurrence, peritoneal metastasis, hepatic metastasis, other distant metastasis and 3-year, 5-year overall survival (OS) rate of two groups were compared. Results 3-year and 5-year OS rates of stage Ⅱ B in study group were similar to those in control group (χ2=0.612,P=0.434). The above rates of stage Ⅲ in study group were higher than those in control group (χ2=3.989,P=0.046). Either the study group or the control group, the 3-year and 5-year OS rates of patients undergone laparoscopic surgery or open surgery were similar (P=0.839, P=0.172). Incidences of local recurrence, peritoneal metastasis and hepatic metastasis in study group were 1.9%, 3.8% and 3.8% respetively, lower than those in control group (8.2%,9.5% and 10.1%,P<0.05). Distant metastasis rate in study group was similar to that in control group. In study group, intraperitoneal chemotherapy regimen with Oxaliplatin had lower rates of peritoneal metastasis and hepatic metastasis as compared to that with Cisplatin (0.9% vs 8.8% ,P=0.019), while the incidences of local recurrence and other distant metastasis were similar. Conclusions Postoperative intraperitoneal chemotherapy combined with systemic chemotherapy improves 3-year and 5-year overall survival rates in patients with stage Ⅲ serosa-involved colorectal cancer, and decreases local recurrence, peritoneal metastasis and liver metastasis rate, especially when intraperitoneal chemotherapy regimen contains Oxaliphtin. Comparing with open surgery, laparoscopic surgery dose not improve 3-year and S-year overall survival rates in patients receiving combined chemotherapy or systemic chemotherapy alone.     

浆膜受侵的结直肠癌术后腹腔化疗联合静脉化疗的临床研究

Objective To compare the clinical efficacy of postoperative intraperitoneal chemotherapy combined with systemic chemotherapy to systemic chemotherapy alone for serosa-involved colorectal cancer. Methods According to the criteria of serosa-involving in colorectal cancer, 332 cases were divided into 2 groups prospectively without randomization. Study group (n=166) was treated with intraperitoneal chemotherapy combined with systemic chemotherapy, and control group (n=166) with systemic chemotherapy alone. Incidence of local recurrence, peritoneal metastasis, hepatic metastasis, other distant metastasis and 3-year, 5-year overall survival (OS) rate of two groups were compared. Results 3-year and 5-year OS rates of stage Ⅱ B in study group were similar to those in control group (χ2=0.612,P=0.434). The above rates of stage Ⅲ in study group were higher than those in control group (χ2=3.989,P=0.046). Either the study group or the control group, the 3-year and 5-year OS rates of patients undergone laparoscopic surgery or open surgery were similar (P=0.839, P=0.172). Incidences of local recurrence, peritoneal metastasis and hepatic metastasis in study group were 1.9%, 3.8% and 3.8% respetively, lower than those in control group (8.2%,9.5% and 10.1%,P<0.05). Distant metastasis rate in study group was similar to that in control group. In study group, intraperitoneal chemotherapy regimen with Oxaliplatin had lower rates of peritoneal metastasis and hepatic metastasis as compared to that with Cisplatin (0.9% vs 8.8% ,P=0.019), while the incidences of local recurrence and other distant metastasis were similar. Conclusions Postoperative intraperitoneal chemotherapy combined with systemic chemotherapy improves 3-year and 5-year overall survival rates in patients with stage Ⅲ serosa-involved colorectal cancer, and decreases local recurrence, peritoneal metastasis and liver metastasis rate, especially when intraperitoneal chemotherapy regimen contains Oxaliphtin. Comparing with open surgery, laparoscopic surgery dose not improve 3-year and S-year overall survival rates in patients receiving combined chemotherapy or systemic chemotherapy alone.     

浆膜受侵的结直肠癌术后腹腔化疗联合静脉化疗的临床研究

Objective To compare the clinical efficacy of postoperative intraperitoneal chemotherapy combined with systemic chemotherapy to systemic chemotherapy alone for serosa-involved colorectal cancer. Methods According to the criteria of serosa-involving in colorectal cancer, 332 cases were divided into 2 groups prospectively without randomization. Study group (n=166) was treated with intraperitoneal chemotherapy combined with systemic chemotherapy, and control group (n=166) with systemic chemotherapy alone. Incidence of local recurrence, peritoneal metastasis, hepatic metastasis, other distant metastasis and 3-year, 5-year overall survival (OS) rate of two groups were compared. Results 3-year and 5-year OS rates of stage Ⅱ B in study group were similar to those in control group (χ2=0.612,P=0.434). The above rates of stage Ⅲ in study group were higher than those in control group (χ2=3.989,P=0.046). Either the study group or the control group, the 3-year and 5-year OS rates of patients undergone laparoscopic surgery or open surgery were similar (P=0.839, P=0.172). Incidences of local recurrence, peritoneal metastasis and hepatic metastasis in study group were 1.9%, 3.8% and 3.8% respetively, lower than those in control group (8.2%,9.5% and 10.1%,P<0.05). Distant metastasis rate in study group was similar to that in control group. In study group, intraperitoneal chemotherapy regimen with Oxaliplatin had lower rates of peritoneal metastasis and hepatic metastasis as compared to that with Cisplatin (0.9% vs 8.8% ,P=0.019), while the incidences of local recurrence and other distant metastasis were similar. Conclusions Postoperative intraperitoneal chemotherapy combined with systemic chemotherapy improves 3-year and 5-year overall survival rates in patients with stage Ⅲ serosa-involved colorectal cancer, and decreases local recurrence, peritoneal metastasis and liver metastasis rate, especially when intraperitoneal chemotherapy regimen contains Oxaliphtin. Comparing with open surgery, laparoscopic surgery dose not improve 3-year and S-year overall survival rates in patients receiving combined chemotherapy or systemic chemotherapy alone.     

浆膜受侵的结直肠癌术后腹腔化疗联合静脉化疗的临床研究

Objective To compare the clinical efficacy of postoperative intraperitoneal chemotherapy combined with systemic chemotherapy to systemic chemotherapy alone for serosa-involved colorectal cancer. Methods According to the criteria of serosa-involving in colorectal cancer, 332 cases were divided into 2 groups prospectively without randomization. Study group (n=166) was treated with intraperitoneal chemotherapy combined with systemic chemotherapy, and control group (n=166) with systemic chemotherapy alone. Incidence of local recurrence, peritoneal metastasis, hepatic metastasis, other distant metastasis and 3-year, 5-year overall survival (OS) rate of two groups were compared. Results 3-year and 5-year OS rates of stage Ⅱ B in study group were similar to those in control group (χ2=0.612,P=0.434). The above rates of stage Ⅲ in study group were higher than those in control group (χ2=3.989,P=0.046). Either the study group or the control group, the 3-year and 5-year OS rates of patients undergone laparoscopic surgery or open surgery were similar (P=0.839, P=0.172). Incidences of local recurrence, peritoneal metastasis and hepatic metastasis in study group were 1.9%, 3.8% and 3.8% respetively, lower than those in control group (8.2%,9.5% and 10.1%,P<0.05). Distant metastasis rate in study group was similar to that in control group. In study group, intraperitoneal chemotherapy regimen with Oxaliplatin had lower rates of peritoneal metastasis and hepatic metastasis as compared to that with Cisplatin (0.9% vs 8.8% ,P=0.019), while the incidences of local recurrence and other distant metastasis were similar. Conclusions Postoperative intraperitoneal chemotherapy combined with systemic chemotherapy improves 3-year and 5-year overall survival rates in patients with stage Ⅲ serosa-involved colorectal cancer, and decreases local recurrence, peritoneal metastasis and liver metastasis rate, especially when intraperitoneal chemotherapy regimen contains Oxaliphtin. Comparing with open surgery, laparoscopic surgery dose not improve 3-year and S-year overall survival rates in patients receiving combined chemotherapy or systemic chemotherapy alone.     

浆膜受侵的结直肠癌术后腹腔化疗联合静脉化疗的临床研究

目的探讨术后腹腔化疗联合静脉化疗与单纯静脉化疗对浆膜受侵的结直肠癌患者的I临床疗效。方法前瞻性非随机将332例浆膜受侵的结直肠癌根治术后患者分为联合化疗组（行腹腔化疗联合静脉化疗166例）和静脉化疗组（行单纯静脉化疗166例）,比较两组患者术后腹腔局部复发率、腹腔转移率、肝及其他远处转移率和患者3年、5年总体生存率。结果联合化疗组和静脉化疗组3年、5年总体生存率：ⅡB期两组病例比较,差异无统计学意义（X^2=0.612,P=0.434）;Ⅲ期病例两组比较,差异有统计学意义（X^2=3.989,P=0.046）。联合化疗组的腹腔局部复发率（1.9％）、腹腔转移率（3.8％）和肝转移率（3.8％）均显著低于静脉化疗组的8.2％、9.5％和10.1％（P〈0.05）,而两组其他远处（肺、骨、脑）转移率（5.1％比3.8％）比较,差异无统计学意义（P〉0.05）。联合化疗组中,使用奥沙利铂组腹腔转移率和肝转移率（0.9％和0.9％）均显著低于使用顺铂组（8.8％和8.8％,P〈0.05）,两组局部复发率和远处转移率（0.9％和4.7％比3.5％和5.3％）比较,差异无统计学意义（P〉0.05）。结论联合化疗可显著降低浆膜受侵的结直肠癌根治术后患者局部复发率、腹腔转移率与肝转移率,腹腔化疗中奥沙利铂在预防腹腔广泛转移和肝转移方面较顺铂效果更佳。     

浆膜受侵的结直肠癌术后腹腔化疗联合静脉化疗的临床研究

Objective To compare the clinical efficacy of postoperative intraperitoneal chemotherapy combined with systemic chemotherapy to systemic chemotherapy alone for serosa-involved colorectal cancer. Methods According to the criteria of serosa-involving in colorectal cancer, 332 cases were divided into 2 groups prospectively without randomization. Study group (n=166) was treated with intraperitoneal chemotherapy combined with systemic chemotherapy, and control group (n=166) with systemic chemotherapy alone. Incidence of local recurrence, peritoneal metastasis, hepatic metastasis, other distant metastasis and 3-year, 5-year overall survival (OS) rate of two groups were compared. Results 3-year and 5-year OS rates of stage Ⅱ B in study group were similar to those in control group (χ2=0.612,P=0.434). The above rates of stage Ⅲ in study group were higher than those in control group (χ2=3.989,P=0.046). Either the study group or the control group, the 3-year and 5-year OS rates of patients undergone laparoscopic surgery or open surgery were similar (P=0.839, P=0.172). Incidences of local recurrence, peritoneal metastasis and hepatic metastasis in study group were 1.9%, 3.8% and 3.8% respetively, lower than those in control group (8.2%,9.5% and 10.1%,P<0.05). Distant metastasis rate in study group was similar to that in control group. In study group, intraperitoneal chemotherapy regimen with Oxaliplatin had lower rates of peritoneal metastasis and hepatic metastasis as compared to that with Cisplatin (0.9% vs 8.8% ,P=0.019), while the incidences of local recurrence and other distant metastasis were similar. Conclusions Postoperative intraperitoneal chemotherapy combined with systemic chemotherapy improves 3-year and 5-year overall survival rates in patients with stage Ⅲ serosa-involved colorectal cancer, and decreases local recurrence, peritoneal metastasis and liver metastasis rate, especially when intraperitoneal chemotherapy regimen contains Oxaliphtin. Comparing with open surgery, laparoscopic surgery dose not improve 3-year and S-year overall survival rates in patients receiving combined chemotherapy or systemic chemotherapy alone.